Repatha vs Xarelto
A side-by-side look at two cardiovascular medications advertised on TV. Informational only — not medical advice.
| CA Repatha | CA Xarelto | |
|---|---|---|
| Generic name | evolocumab | rivaroxaban |
| Drug class | PCSK9 Inhibitor (Biologic) | Factor Xa Inhibitor |
| Treats | High cholesterol, cardiovascular disease | Blood clots, atrial fibrillation |
| Category | Cardiovascular | Cardiovascular |
| Manufacturer | Amgen | Bayer/Janssen |
| Year approved | 2015 | 2012 |
| FDA warning | No boxed warning | Black box warning |
| Est. TV ad spend | $32M | $28M |
| Common side effects | Injection site reactions, Allergic reactions, Back pain, Fatigue | Serious bleeding risk, Bruising, Prolonged bleeding, Dizziness |
Frequently asked questions
Is Repatha or Xarelto better?
Neither is universally "better." Repatha (evolocumab) and Xarelto (rivaroxaban) are both used for cardiovascular, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Repatha and Xarelto?
Repatha is a PCSK9 Inhibitor (Biologic) made by Amgen, while Xarelto is a Factor Xa Inhibitor made by Bayer/Janssen. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Repatha has the larger estimated TV advertising budget of the two.